idecabtagene vicleucel
bms,2seventy bio
['ide-cel', 'karmma']
#ash22 from presented work exploring the prognostic value of the depth of serological and mrd response in patients with mm, after car t cell therapy. a karmma trial update #myeloma 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma